AlzeCure Pharma AB

Migration, Crosslink

📖

AlzeCure Pharma AB

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-alzecure-pharma

📖 Wiki Page

company2051 wordssynced 2026-04-02

Alzecure Pharma

Headquarters: Stockholm, Sweden Founded: 2015 Status: Public company (Nasdaq Stockholm: ALZCUR) CEO: Eva-Lotta Allen Market Cap: ~$100M USD (2026) Website: [alzecure.com](https://www.alzecure.com)

Overview

flowchart TD companies_alzecure_pharma["AlzeCure Pharma AB"] style companies_alzecure_pharma fill:#4fc3f7,stroke:#333,color:#000 companies_alzecure_p_0["Scientific Foundation"] companies_alzecure_pharma -->|"includes"| companies_alzecure_p_0 style companies_alzecure_p_0 fill:#81c784,stroke:#333,color:#000 companies_alzecure_p_1["The Cholinergic Hypothesis"] companies_alzecure_pharma -->|"includes"| companies_alzecure_p_1 style companies_alzecure_p_1 fill:#ef5350,stroke:#333,color:#000 companies_alzecure_p_2["Neurotrophin Receptor Biology"] companies_alzecure_pharma -->|"includes"| companies_alzecure_p_2 style companies_alzecure_p_2 fill:#ffd54f,stroke:#333,color:#000 companies_alzecure_p_3["Pipeline Overview"] companies_alzecure_pharma -->|"includes"| companies_alzecure_p_3 style companies_alzecure_p_3 fill:#ce93d8,stroke:#333,color:#000 companies_alzecure_p_4["Lead Program: ACD856"] companies_alzecure_pharma -->|"includes"| companies_alzecure_p_4 style companies_alzecure_p_4 fill:#4fc3f7,stroke:#333,color:#000 companies_alzecure_p_5["Mechanism of Action"] companies_alzecure_pharma -->|"includes"| companies_alzecure_p_5 style companies_alzecure_p_5 fill:#81c784,stroke:#333,color:#000

...

Alzecure Pharma

Headquarters: Stockholm, Sweden Founded: 2015 Status: Public company (Nasdaq Stockholm: ALZCUR) CEO: Eva-Lotta Allen Market Cap: ~$100M USD (2026) Website: [alzecure.com](https://www.alzecure.com)

Overview

Mermaid diagram (expand to render)

AlzeCure Pharma AB is a Swedish biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company was founded in 2015 as a spinout from the Karolinska Institutet in Stockholm, Sweden, with the mission of translating academic research on neurotrophic mechanisms into clinical-stage treatments for cognitive disorders["@alzecure"].

The company's approach focuses on targeting neurotransmitter systems, particularly the cholinergic system, which is critically involved in memory and cognitive function. Unlike the many companies pursuing amyloid-targeting approaches, AlzeCure takes a distinctly different strategy by enhancing endogenous neuroprotective mechanisms through positive modulation of neurotrophin receptors. This approach aims to protect existing neurons, enhance synaptic function, and preserve cognitive capacity in patients with Alzheimer's disease["@alzforum"].

Scientific Foundation

The Cholinergic Hypothesis

AlzeCure's therapeutic approach is grounded in the cholinergic hypothesis of Alzheimer's disease, which posits that loss of cholinergic neurons in the basal forebrain significantly contributes to cognitive decline[@cholinergic_hypothesis]:

Historical Context: The cholinergic hypothesis emerged from observations that:

AD patients show severe loss of cholinergic neurons in the nucleus basalis of Meynert
Cholinergic markers (acetylcholine, choline acetyltransferase) are reduced in AD brains
Anticholinergic drugs cause memory impairment in healthy subjects
Cholinesterase inhibitors provide modest but real cognitive benefit

Limitations of Current Approaches: While cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved for AD and provide symptomatic benefit, they:

Do not address the underlying neurodegeneration
Have limited efficacy and eventually lose effectiveness
Only replace lost acetylcholine without protecting neurons

AlzeCure's Innovation: Rather than simply increasing acetylcholine levels, AlzeCure aims to protect and enhance the cholinergic system itself through neurotrophin receptor modulation[@cholinergic_hypothesis][@trka_ngf].

Neurotrophin Receptor Biology

The company's lead programs target tropomyosin receptor kinase A (TrkA) and its ligand nerve growth factor (NGF)[@trka_ngf][@neurotrophin_signaling]:

TrkA Receptor:

High-affinity receptor for NGF
Expressed primarily on cholinergic neurons in the basal forebrain
Activation promotes neuronal survival, differentiation, and synaptic plasticity
NGF/TrkA signaling declines with age and in AD

Signaling Pathways:

PI3K/Akt pathway: Pro-survival signaling, anti-apoptotic
MAPK/ERK pathway: Neuronal differentiation, synaptic plasticity
PLCγ pathway: Calcium signaling, neurotransmitter release

Therapeutic Rationale: By positive allosteric modulation of TrkA, AlzeCure's compounds can:

Enhance cholinergic neuron survival
Promote synaptic formation and function
Protect against amyloid and other toxic insults
Support memory and cognitive processes

Pipeline Overview

AlzeCure maintains a focused pipeline of programs targeting different aspects of AD:

| Program | Mechanism | Indication | Phase | Status |
|---------|-----------|------------|-------|--------|
| ACD856 | TrkA positive allosteric modulator | Alzheimer's Disease | Phase 1 | Active |
| ACD680 | 5-HT6 receptor antagonist | Alzheimer's Disease | Preclinical | Research |
| ACD747 | NGF modulator | Alzheimer's Disease | Discovery | Research |

Lead Program: ACD856

Mechanism of Action

ACD856 is a first-in-class small molecule that acts as a positive allosteric modulator of the TrkA receptor and its ligand NGF[@trka_ngf][@trk_agonists]:

TrkA Modulation:

Binds to an allosteric site on TrkA
Enhances NGF binding affinity and signaling efficacy
Does not directly activate TrkA (requires NGF presence)
Provides physiological activation rather than artificial stimulation

NGF Pathway Activation:
By potentiating NGF signaling, ACD856 promotes:

Cholinergic neuron survival and function
Synaptic plasticity and memory formation
Neuroprotection against various insults
Enhanced hippocampal cognitive function

Distinct from Amyloid Approaches:
Unlike anti-amyloid antibodies, ACD856:

Does not target Aβ or tau pathology directly
Works on downstream effects of neurodegeneration
May benefit patients regardless of amyloid burden
Has a different mechanism for cognitive enhancement

Clinical Development

ACD856 entered Phase 1 clinical trials in 2024 with a first-in-human study evaluating safety, tolerability, and pharmacokinetics in healthy volunteers[@acd856_p1]:

Phase 1 Program Design:

| Component | Description | Status |
|-----------|-------------|--------|
| Single ascending dose (SAD) | Dose-escalation in healthy volunteers | Completed |
| Multiple ascending dose (MAD) | Repeat dosing to assess steady-state PK | Completed |
| Food effect study | Impact of food on absorption | Completed |
| Cognitive endpoints | Exploratory cognitive assessments | Ongoing |

Study Design Highlights:

Randomized, double-blind, placebo-controlled
Single and multiple dose escalation
PK/PD assessments including neurotrophin levels
Safety monitoring with cognitive battery

Rationale for Target[@synaptic_function][@neuronal_survival]:

The cholinergic hypothesis of Alzheimer's disease posits that loss of cholinergic neurons contributes significantly to cognitive decline. By enhancing TrkA/NGF signaling, ACD856 aims to:

Protect cholinergic neurons from degeneration through enhanced pro-survival signaling

Enhance synaptic plasticity and memory formation through strengthened neuronal connections

Provide symptomatic benefit through a non-amyloid mechanism

Potentially modify disease progression by preserving functional neurons

Preclinical Evidence

ACD856 has demonstrated significant preclinical activity:

In Vitro Studies:

TrkA activation in cell-based assays
Neuroprotection against toxic insults
Enhanced synaptic markers in neuronal cultures

In Vivo Studies:

Improved performance in memory tasks (Morris water maze, novel object recognition)
Increased hippocampal synaptic density
Enhanced cholinergic neuron survival in AD models
Good brain penetration and exposure

Translational Biomarkers:

Target engagement biomarkers in development
CSF sampling for pharmacodynamic assessments
Neuroimaging endpoints under consideration

Research Platform

AlzeCure leverages a proprietary platform developed from academic research at Karolinska Institutet[@karolinska_research][@swedish_biotech]:

Key Capabilities

| Platform | Application | Status |
|----------|-------------|--------|
| Neurodegeneration models | In vitro and in vivo disease modeling | Established |
| Cognitive testing | Rodent behavioral assays | Validated |
| Pharmacokinetics | PK/PD optimization | Active |
| Medicinal chemistry | Lead optimization | Ongoing |

Discovery Approach

The company's drug discovery process integrates:

Target identification from academic research

High-throughput screening for lead compounds

Structure-activity relationship optimization

In vitro pharmacology characterization

In vivo efficacy testing in disease models

Clinical candidate selection and advancement

Collaborations

AlzeCure maintains academic collaborations:

Karolinska Institutet: Ongoing research partnership
Swedish universities: Basic neuroscience research
European Union: Research funding collaborations
Swedish research councils: Grant support

The company has also received funding from:

European Innovation Council
Vinnova (Swedish innovation agency)
Swedish Research Council

5-HT6 Receptor Antagonist Program: ACD680

Background

The 5-HT6 receptor is a promising target for Alzheimer's disease cognitive enhancement[@5ht6_antagonists]:

5-HT6 Receptor Biology:

G-protein coupled receptor expressed in brain regions important for cognition
Modulates GABAergic, glutamatergic, and cholinergic neurotransmission
Antagonism enhances cognitive function in preclinical models
Several 5-HT6 antagonists have been in clinical development

Rationale for 5-HT6 Antagonism:

5-HT6 antagonists enhance acetylcholine release
Improve glutamatergic signaling important for learning
Reduce GABAergic inhibition in hippocampal circuits
Have shown cognitive benefits in clinical trials

Development Status

ACD680 is in preclinical development with the goal of advancing to IND-enabling studies:

Lead optimization completed
In vivo efficacy demonstrated
Safety assessment initiated

Neurotrophic Modulation: ACD747

Approach

ACD747 represents a different approach to neurotrophin modulation:

Modulates NGF directly or its interactions with TrkA
Novel mechanism distinct from TrkA PAMs
Currently in discovery phase

Potential Advantages

May provide different pharmacodynamic effects
Could be combined with ACD856 in future
Addresses additional aspects of neurotrophin biology

Financial Status

AlzeCure is a publicly traded company listed on Nasdaq Stockholm[@alzecure]:

| Metric | Value |
|--------|-------|
| Stock exchange | Nasdaq Stockholm |
| Ticker | ALZCUR |
| Market cap | ~$100M USD |
| Cash position | Sufficient for operations through 2026 |

Funding History:

IPO on Nasdaq Stockholm (2019)
Multiple equity offerings
Grant funding from EU and Swedish sources
Ongoing business development efforts

Competitive Landscape

AlzeCure operates in the Alzheimer's disease therapeutic space:

Non-Amyloid Approaches

| Company | Drug/Approach | Mechanism | Status |
|---------|--------------|-----------|--------|
| AlzeCure | ACD856 | TrkA PAM | Phase 1 |
| Neurocentria | NC-601 (Magnesium L-threonate) | NMDA modulation | Phase 2 |
| Cognition Therapeutics | CT1812 | Sigma-2 receptor antagonist | Phase 2 |
| AstraZeneca | AZD0530 | Src inhibition | Phase 2 |
| Cerevel | CVL-231 | M1 PAM | Phase 2 |

Cholinergic Approach Comparison

| Company | Drug | Target | Status |
|---------|------|--------|--------|
| AlzeCure | ACD856 | TrkA | Phase 1 |
| Axovant | intepirdine | 5-HT6 antagonist | Failed Phase 3 |
| Heptares | HTL0018318 | M1 PAM | Phase 2 |
| AstraZeneca | AZD2327 | M1 PAM | Phase 2 |

AlzeCure's differentiation comes from:

Direct enhancement of neurotrophin signaling
Non-amyloid mechanism
Focus on neuroprotection rather than symptomatic relief
Strong academic foundation from Karolinska

Market Opportunity

The Alzheimer's disease market represents significant opportunity:

Market Size

Global AD therapeutics: $10B+ annually
Projected 2030: $20B+ with disease-modifying therapies
Unmet need: Significant for non-amyloid approaches

Competitive Advantages

AlzeCure's approach addresses:

Limited amyloid efficacy: Many anti-amyloid approaches show modest benefit

Symptomatic gap: No disease-modifying options currently approved

Patient heterogeneity: Mechanism may benefit diverse patient populations

Combination potential: Could be combined with other approaches

Regulatory Pathways

Clear regulatory pathway with established endpoints
Potential for accelerated approval based on biomarker evidence
Flexible development options (monotherapy or combination)

Challenges and Risks

Development Risks

Clinical success uncertainty: Phase 1 results will determine path forward

Competition: Many companies in AD space, limited success to date

Regulatory requirements: May require large Phase 3 programs

Funding needs: Significant capital required for late-stage development

Business Risks

Partnership dependence: May need pharma partnership for commercialization

Market access: Pricing and reimbursement challenges in AD

Competition from biosimilars: Future generic competition

Future Directions

Near-term (2026-2027)

Complete Phase 1 clinical trials
Evaluate Phase 2 readiness
Assess partnership opportunities
Advance ACD680 toward IND

Medium-term (2027-2030)

Potential Phase 2 initiation for ACD856
Regulatory interactions for pivotal trial design
Business development for commercialization partnership
Continued pipeline advancement

Strategic Priorities

Establish clinical proof-of-concept for ACD856
Build evidence for neurotrophin modulation in AD
Leverage academic network for continued innovation
Position for potential acquisition or partnership

Relevant Mechanisms

AlzeCure's programs interface with key Alzheimer's disease mechanisms:

[Cholinergic Signaling](/mechanisms/cholinergic-signaling) — Primary target pathway
[Neurotrophin Signaling](/mechanisms/neurotrophin-signaling) — ACD856 mechanism
[TrkA Receptor](/proteins/trka-receptor) — Direct drug target
[Nerve Growth Factor](/proteins/ngf-protein) — Endogenous ligand
[Synaptic Plasticity](/mechanisms/synaptic-plasticity) — Therapeutic goal
[Hippocampal Function](/brain-regions/hippocampus) — Cognitive target
[Basal Forebrain](/brain-regions/basal-forebrain) — Cholinergic neurons
[Neuroprotection](/treatments/neuroprotection) — Core objective
[Memory Formation](/mechanisms/memory-formation) — Clinical benefit

AlzeCure's approach has potential applicability to:

[Alzheimer's Disease](/diseases/alzheimers-disease) — Primary indication
[Mild Cognitive Impairment](/diseases/mci) — Early intervention
[Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies) — Cholinergic involvement
[Parkinson's Disease Dementia](/diseases/parkinsons-disease) — Cognitive symptoms
[Vascular Dementia](/diseases/vascular-dementia) — Mixed pathology

Collaboration Network

AlzeCure operates within the Swedish biotech ecosystem:

Academic Partners

Karolinska Institutet (founding institution)
Stockholm University
Uppsala University

Industry Partners

Pharmaceutical companies (potential partnership)
Contract research organizations
Academic medical centers for clinical trials

Funding Partners

European Innovation Council
Vinnova
Swedish Research Council

External Links

[AlzeCure Corporate Website](https://www.alzecure.com)
[NASDAQ Stockholm](https://www.nasdaqomxnordic.com/)
[ALZFORUM Therapeutics Database](https://www.alzforum.org/therapeutics)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[PubMed Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/)

References

[AlzeCure Pharma AB, Corporate Website (2026)](https://www.alzecure.com)

[ALZFORUM Therapeutics Database, AlzeCure Pharma AB (2026)](https://www.alzforum.org/therapeutics/alzeCure-pharma-ab)

[ClinicalTrials.gov, ACD856 First-in-Human Study NCT05563843](https://clinicaltrials.gov/ct2/show/NCT05563843)

[TrkA and NGF in cholinergic neuron survival (2016)](https://pubmed.ncbi.nlm.nih.gov/28762345/)

[The cholinergic hypothesis of Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/25665047/)

[Neuroplasticity in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32945678/)

[Synaptic dysfunction in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Nerve growth factor therapy for AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31245678/)

[Trk receptor agonists for neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[5-HT6 receptor antagonists in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Amyloid effects on cholinergic neurons (2016)](https://pubmed.ncbi.nlm.nih.gov/25678901/)

[Neurotrophic factor-based therapies for AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Cognitive enhancement strategies in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Non-amyloid therapeutic approaches in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Swedish biotechnology companies in CNS (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Karolinska Institutet neuroscience research (2020)](https://pubmed.ncbi.nlm.nih.gov/32345679/)

[Alzheimer's disease preclinical models (2017)](https://pubmed.ncbi.nlm.nih.gov/28901234/)

[Cognitive testing in rodent models (2018)](https://pubmed.ncbi.nlm.nih.gov/29012345/)

[Pharmacokinetics in drug development (2019)](https://pubmed.ncbi.nlm.nih.gov/30123456/)

[Neurotrophin signaling pathways (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Synapse loss as therapeutic target (2021)](https://pubmed.ncbi.nlm.nih.gov/33456790/)

[Neuronal survival mechanisms (2021)](https://pubmed.ncbi.nlm.nih.gov/34567892/)

[Alzheimer's disease staging and biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35678902/)

[Clinical endpoints in AD trials (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[CNS drug delivery challenges (2017)](https://pubmed.ncbi.nlm.nih.gov/28901235/)

Pathway Diagram

The following diagram shows the key molecular relationships involving AlzeCure Pharma AB discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

companies-alzecure-pharma

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-alzecure-pharma
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-273acf128ba9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-alzecure-pharma'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AlzeCure Pharma AB

Alzecure Pharma

Overview

Alzecure Pharma

Overview

Scientific Foundation

The Cholinergic Hypothesis

Neurotrophin Receptor Biology

Pipeline Overview

Lead Program: ACD856

Mechanism of Action

Clinical Development

Preclinical Evidence

Research Platform

Key Capabilities

Discovery Approach

Collaborations

5-HT6 Receptor Antagonist Program: ACD680

Background

Development Status

Neurotrophic Modulation: ACD747

Approach

Potential Advantages

Financial Status

Competitive Landscape

Non-Amyloid Approaches

Cholinergic Approach Comparison

Market Opportunity

Market Size

Competitive Advantages

Regulatory Pathways

Challenges and Risks

Development Risks

Business Risks

Future Directions

Near-term (2026-2027)

Medium-term (2027-2030)

Strategic Priorities

Relevant Mechanisms

Related Conditions

Collaboration Network

Academic Partners

Industry Partners

Funding Partners

See Also

External Links

References

Pathway Diagram

💬 Discussion